See this earlier post:
↪ Daraxonrasib raised 1-year survival from 18.7% to 53.3% in pancreatic cancer (NEJM)
#pancreaticcancerHD #daraxonrasibHD #cancerHD #rasHD #ascoHD #rasolute302HD
A shared CBS News item reporting that a new experimental drug nearly doubled survival in advanced pancreatic cancer. Little detail beyond the headline.
See this earlier post:
↪ Daraxonrasib raised 1-year survival from 18.7% to 53.3% in pancreatic cancer (NEJM)
#pancreaticcancerHD #daraxonrasibHD #cancerHD #rasHD #ascoHD #rasolute302HD
A new, experimental medication nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a study published Sunday. New drug nearly doubles survival rates in some pancreatic cancer patients, study says (CBS News)